Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service peripheral nerve stimulation & intrathecal pumps cases in Massachusetts: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 11% on average (174 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 7 | 483 | 28% |
| 2020 | 8 | 367 | 30% |
| 2021 | 11 | 670 | 32% |
| 2022 | 11 | 848 | 35% |
| 2023 | 16 | 722 | 38% |
| 2024 | 17 | 831 | 39% |
| 2025 from claims | – | 616 498–723 | 40% |
| 2026 forecast | – | 658 516–827 | 39% |
| 2027 forecast | – | 695 515–919 | 40% |
| 2028 forecast | – | 734 519–1,013 | 40% |
| 2029 forecast | – | 774 526–1,110 | 40% |
| 2030 forecast | – | 817 535–1,213 | 40% |
PNS lead and generator, intrathecal pump and catheter. Professional codes (what the surgeon bills): CPT 64555, 64590, 62362, 62350.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 75% of the cases CMS names in Massachusetts; 12 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 3% inpatient hospital, 91% hospital outpatient, 6% surgery center. The share outside the hospital has moved −10 pts since 2019.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Surgery center |
|---|---|---|---|
| 2026 · ~660 | ~18 | ~590 | ~55 |
| 2027 · ~700 | ~18 | ~610 | ~67 |
| 2028 · ~730 | ~19 | ~640 | ~76 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: surgery center about 10% (6% in 2025), hospital outpatient about 87% (91% in 2025). More of these cases each year are decided in surgery centers, where the surgeons often own the center and weigh price and turnaround.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 22 | 1,267+7.6%/yr | +7.6%/yr | 0.6 | 39% | 2,170 in 2030+9.4%/yr |
| Pennsylvania | 15 | 1,231+6.1%/yr | +6.1%/yr | 0.8 | 44% | 1,540 in 2030+3.8%/yr |
| New Jersey | 8 | 739+5.9%/yr | +5.9%/yr | 0.7 | 58% | 950 in 2030+4.2%/yr |
| Connecticut | 5 | 276+9.9%/yr | +9.9%/yr | 0.8 | 30% | 610 in 2030+14%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Radiofrequency ablation (facet, genicular, basivertebral) | 107 | 7,050+1.9%/yr | +1.9%/yr | 7.21.0× | 43% | 9,910 in 2030+5.8%/yr |
| Spinal cord & DRG stimulation | 5 | 264−7.2%/yr | −7.2%/yr | 0.30.7× | 15% | 380 in 2030+6.4%/yr |
Peripheral nerve stimulation & intrathecal pumps in every state, and its device makers · Every procedure market in Massachusetts · Every state · Compare with New York
Mml leads with 68% of company spending on these surgeons in 2025, −12 pts on 2024.
In 2025, 11 companies reported engagement with Massachusetts’s surgeons worth $132K in consulting, speaking, meals and travel tied to these products, about $7,747 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 13 clearances and approvals in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.